Targeting the spectrum of immune checkpoints in prostate cancer

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955–972.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–988.
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–547.
   PubMed Web of Science ®Google Scholar
• Lo B, Abdel-Motal UM. Lessons from CTLA-4 deficiency and checkpoint inhibition. Curr Opin Immunol. 2017;49:14–19.
   PubMed Web of Science ®Google Scholar
• Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 2010;11(2):129–135.
   PubMed Web of Science ®Google Scholar
• Perkins D, Wang Z, Donovan C, et al. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 1996;156(11):4154–4159.
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 2009;229(1):12–26.
   PubMed Web of Science ®Google Scholar
• Tai X, Van Laethem F, Sharpe AH, et al. Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation. Proc. Natl. Acad. Sci. U. S. A. 2007;104(34):13756–13761.
   PubMed Web of Science ®Google Scholar
• Kong K-F, Fu G, Zhang Y, et al. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 2014;15(5):465–472.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275 .
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009;206(8):1717–1725.
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 2001;194(4):481–489.
   PubMed Web of Science ®Google Scholar
• Fassò M,  Waitz R, Hou Y, et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc. Natl. Acad. Sci. U. S. A. 2008;105(9):3509–3514.
   PubMed Web of Science ®Google Scholar
• Gubin MM,  Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–581 .
   PubMed Web of Science ®Google Scholar
• Wei SC,  Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–1133.e17.
   Web of Science ®Google Scholar
• Simpson TR,  Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013;210(9):1695–1710.
   PubMed Web of Science ®Google Scholar
• Pai -C-CS, Simons DM, Lu X, et al. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J. Clin. Invest. 2019;129(1):349–363.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I, et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006;203(4):883–895.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004;173(2):945–954.
   PubMed Web of Science ®Google Scholar
• Sheppard K-A,  Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1–3):37–41.
   PubMed Web of Science ®Google Scholar
• Wei F,Zhong S, Ma Z, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl. Acad. Sci. U. S. A. 2013;110(27):E2480–9.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–1251.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 2015;6(1):6692.
   PubMedGoogle Scholar
• Francisco LM,  Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009;206(13):3015–3029.
   PubMed Web of Science ®Google Scholar
• Strauss L, Mahmoud MAA, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci. Immunol. 2020;5(43):eaay1863.
   PubMed Web of Science ®Google Scholar
• Nishimura H,Okazaki T, Tanaka Y, et al.Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–322.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151.
   PubMed Web of Science ®Google Scholar
• Wang J,  Yoshida T, Nakaki F, et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U. S. A. 2005;102(33):11823–11828.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM,  Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 2016;375(9):819–829.
   PubMed Web of Science ®Google Scholar
• Gao J,  Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397–404.e9.
   PubMed Web of Science ®Google Scholar
• Manguso RT,  Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413–418.
   PubMed Web of Science ®Google Scholar
• Kwon ED,  Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Drake CG, Beer TM, et al.Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur. Urol. 2020;78(6):822–830.
   PubMed Web of Science ®Google Scholar
• Beer TM,  Kwon ED, Drake CG, et al. randomized, double-blind, phase iii trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 2017;35(1):40–47.
   PubMed Web of Science ®Google Scholar
• Topalian SL,  Hodi FS, Brahmer JR, et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810–52817.
   PubMed Web of Science ®Google Scholar
• Hansen AR,Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 2018;29(8):1807–1813.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES,  Piulats JM, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: multicohort, Open-Label Phase II KEYNOTE-199 Study. J. Clin. Oncol. 2020;38(5):395–405.
   PubMed Web of Science ®Google Scholar
• Hoimes CJ, Graff JN, Tagawa ST, et al. KEYNOTE-199 cohorts (C) 4 and 5: phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2020;38(15_suppl):5543.
   Google Scholar
• Boudadi K, Suzman DL, Anagnostou V, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9(47):28561–28571.
   PubMedGoogle Scholar
• Sharma P,Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38(4):489–499.e3.
   PubMed Web of Science ®Google Scholar
• Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 2017;23(5):551–555.
   PubMed Web of Science ®Google Scholar
• Trujillo JA, Sweis RF, Bao R,Sweis RF, Bao R, et al.  T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol. Res. 2018;6(9):990–1000.
   PubMed Web of Science ®Google Scholar
• Ji -R-R, Chasalow SD, Wang L, et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 2012;61(7):1019–1031.
   PubMed Web of Science ®Google Scholar
• Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 2020;12(537):eaaz3577.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 2017;127(8):2930–2940.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Guo C, Gurel B, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20(8):455–469.
   PubMed Web of Science ®Google Scholar
• Tamborero D, Rubio-Perez C, Muiños F, et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin. Cancer Res. 2018;24(15):3717–3728.
   PubMed Web of Science ®Google Scholar
• Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation. 2018;128(10):4441–4453.
   PubMed Web of Science ®Google Scholar
• Mendonca J, Kumar R, Owoyemi O, et al. Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy. bioRxiv. 2020; DOI:https://doi.org/10.1101/2020.09.10.286252.
   Google Scholar
• Brady L, Kriner M, Coleman I, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat. Commun. 2021;12(1). DOI:https://doi.org/10.1038/s41467-021-21615-4.
   Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571 .
   PubMed Web of Science ®Google Scholar
• He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. bioRxiv. 2020; DOI:https://doi.org/10.1101/2020.03.19.998450.
   Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019;51(2):202–206.
   PubMed Web of Science ®Google Scholar
• Li G-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85–98.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J. Clin. Invest. 2016;126(6):2334–2340.
   PubMed Web of Science ®Google Scholar
• Gong J, Wang C, Lee PP, et al. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. J. Natl. Compr. Canc. Netw. 2017;15(2):142–147.
   PubMed Web of Science ®Google Scholar
• Lee L, Ali S, Genega E, et al. Aggressive-variant microsatellite-stable POLE mutant prostate cancer with high mutation burden and durable response to immune checkpoint inhibitor therapy. JCO Precis Oncol. 2018;1–8.
   Google Scholar
• Ryan MJ, Bose R. Genomic alteration burden in advanced prostate cancer and therapeutic implications. Front Oncol. 2019;9(1287). DOI:https://doi.org/10.3389/fonc.2019.01287
   Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Sena LA, Fountain J, Isaacsson Velho P, et al. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncologist. 2021;26(2):e270–e278; DOI:https://doi.org/10.1002/onco.13601.
   PubMed Web of Science ®Google Scholar
• Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLOS ONE. 2020;15(5):e0233260.
   PubMed Web of Science ®Google Scholar
• Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020;8(2):e001065.
   PubMed Web of Science ®Google Scholar
• Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471–478.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Eur. Urol. 2019;75(3):378–382.
   PubMed Web of Science ®Google Scholar
• Wu Y-M, Cieślik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173(7):1770–1782.e14.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES. Cyclin-dependent kinase 12, immunity, and prostate cancer. N. Engl. J. Med. 2018;379(11):1087–1089.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Isaacsson Velho P, Fu W, et al. CDK12 -Altered Prostate Cancer: clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors . JCO Precis Oncol. 2020;4(4):370–381 .
   PubMedGoogle Scholar
• Schweizer MT, Ha G, Gulati R, et al. CDK12-Mutated Prostate Cancer: clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precis Oncol. 2020;4(4):382–392.
   PubMedGoogle Scholar
• Samstein RM, Krishna C, Ma X, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2020;1(12):1188–1203.
   PubMedGoogle Scholar
• Linnebacher M, Gebert J, Rudy W, et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001;93(1):6–11.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, et a. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009–1021.
   PubMed Web of Science ®Google Scholar
• O’Donnell T, Christie EL, Ahuja A, et al. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer. 2018;18(1):87.
   PubMedGoogle Scholar
• Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 2013;62(1):137–147.
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 2014;106(11). DOI:https://doi.org/10.1093/jnci/dju268.
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther. 2017;6:11–16.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Eickhoff JC, Wargowski E, et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9(39):25586–25596.
   PubMedGoogle Scholar
• McNeel DG, Becker JT, Eickhoff JC, et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin. Cancer Res. 2014;20(14):3692–3704.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Eickhoff JC, Ferrari AC, et al. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2020;26(19):5162–5171.
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097–1100.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 2011;208(10):2005–2016.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu. Rev. Immunol. 2015;33(1):445–474.
   PubMedGoogle Scholar
• Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571–580.
   PubMed Web of Science ®Google Scholar
• Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010;70(7):2595–2603.
   PubMed Web of Science ®Google Scholar
• van Soest RJ, Templeton AJ, Vera-Badillo FE, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann. Oncol. 2015;26(4):743–749.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Crabb SJ, Jones RJ, et al. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. PLoS One. 2016;11(7):e0158952.
   PubMed Web of Science ®Google Scholar
• Zarif JC, Baena-Del Valle JA, Hicks JL, et al. Mannose receptor-positive macrophage infiltration correlates with prostate cancer onset and metastatic castration-resistant disease. Eur. Urol. Oncol. 2019;2(4):429–436.
   PubMed Web of Science ®Google Scholar
• Lundholm M, Hägglöf C, Wikberg ML, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci. Rep. 2015;5(1):15651.
   PubMedGoogle Scholar
• Di Mitri D, Mirenda M, Vasilevska J, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 2019;28(8):2156–2168.e5.
   PubMed Web of Science ®Google Scholar
• Jaynes JM, Sable R, Ronzetti M, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 2020;12(530):eaax6337.
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010;16(18):4583–4594.
   PubMed Web of Science ®Google Scholar
• Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–732.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib eradicates advanced Murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 2017;7(7):750–765.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Loriot Y, McGregor BA, et al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of Cohort 6 of the COSMIC-021 Study. J. Clin. Oncol. 2020;38(6_suppl):139.
   Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548.
   PubMed Web of Science ®Google Scholar
• Jairath NK, Farha MW, Srinivasan S, et al. Tumor immune microenvironment clusters in localized prostate adenocarcinoma: prognostic impact of macrophage enriched/plasma cell non-enriched subtypes. J. Clin. Med. 2020;9(6):1973.
   PubMed Web of Science ®Google Scholar
• Weiner AB, Vidotto T, Liu Y, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat. Commun. 2021;12(1). DOI:https://doi.org/10.1038/s41467-021-21245-w.
   Google Scholar
• Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020;369(6506):921–922.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2015;42(1):199 .
   Web of Science ®Google Scholar
• Ager CR, Reilley MJ, Nicholas C, et al. Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol. Res. 2017;5(8):676–684.
   PubMed Web of Science ®Google Scholar
• Ding L, Kim H-J, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972–2980.e5.
   PubMed Web of Science ®Google Scholar
• Reisländer T, Lombardi EP, Groelly FJ, et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat. Commun. 2019;10(1). DOI:https://doi.org/10.1038/s41467-019-11048-5.
   Google Scholar
• Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79(2):311–319.
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Wang H, Agarwal N, et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol. 2021;JCO2002759.
   Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Desdín-Micó G, Soto-Heredero G, Aranda JF, et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 2020;368(6497):1371–1376.
   PubMed Web of Science ®Google Scholar
• Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer. J. Thorac. Oncol. 2019;14(3):547–552.
   PubMed Web of Science ®Google Scholar
• Betof AS, Nipp RD, Giobbie-Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963–971.
   PubMed Web of Science ®Google Scholar
• Heng TSP, Goldberg GL, Gray DHD, et al. Effects of castration on thymocyte development in two different models of thymic involution. J. Immunol. 2005;175(5):2982–2993.
   PubMed Web of Science ®Google Scholar
• Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 2005;175(4):2741–2753.
   PubMed Web of Science ®Google Scholar
• Viselli SM, Stanziale S, Shults K, et al. Castration alters peripheral immune function in normal male mice. Immunology. 1995;84(2):337–342.
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody ADH, Mihalyo MA, et al Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7(3):239–249.
   PubMed Web of Science ®Google Scholar
• Obradovic AZ, Dallos MC, Zahurak ML, et al. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clin. Cancer Res. 2020;26(13):3182–3192.
   PubMed Web of Science ®Google Scholar
• Kissick HT, Sanda MG, Dunn LK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc. Natl. Acad. Sci. U. S. A. 2014;111(27):9887–9892.
   PubMed Web of Science ®Google Scholar
• Liva SM, Voskuhl RR. Testosterone Acts Directly on CD4+ T Lymphocytes to Increase IL-10 Production. J. Immunol. 2001;167(4):2060–2067.
   PubMed Web of Science ®Google Scholar
• Markman JL, Porritt RA, Wakita D, et al. Loss of testosterone impairs anti-tumor neutrophil function. Nat. Commun. 2020;11(1). DOI:https://doi.org/10.1038/s41467-020-15397-4.
   Google Scholar
• Antonarakis ES, Kibel AS, Yu EY, et al. Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial. Clin. Cancer Res. 2017;23(10):2451–2459.
   PubMed Web of Science ®Google Scholar
• Pu Y, Xu M, Liang Y, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci. Transl. Med. 2016;8(333):333ra47–333ra47.
   PubMed Web of Science ®Google Scholar
• Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20(1):28–35.
   PubMed Web of Science ®Google Scholar
• Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1). https://doi.org/10.1186/s40425-018-0360-8
   Google Scholar
• Leclerc BG, Charlebois R, Chouinard G, et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer Res. 2016;22(1):158–166.
   PubMed Web of Science ®Google Scholar
• Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol. Oncol. Res. 2013;19(4):811–814.
   PubMed Web of Science ®Google Scholar
• Zylka MJ, Sowa NA, Taylor-Blake B, et al. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron. 2008;60(1):111–122.
   PubMed Web of Science ®Google Scholar
• Goswami S, Apostolou I, Zhang J, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 2018;128(9):3813–3818.
   PubMed Web of Science ®Google Scholar
• Morel KL, Sheahan AV, Burkhart DL, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444–456.
   PubMedGoogle Scholar
• Powderly J, Cote G, Flaherty K, et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer. 2015;3(Suppl 2):O8.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 2018;24(20):4960–4967.
   PubMed Web of Science ®Google Scholar
• Katsurada M, Nagano T, Tachihara M, et al. Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer. Anticancer Res. 2019;39(2):815–825.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Vitkin N, Nersesian S, Siemens DR, et al. The tumor immune contexture of prostate cancer. Front Immunol. 2019;10(603). https://doi.org/10.3389/fimmu.2019.00603
   Google Scholar
• Kiniwa Y, Miyahara Y, Wang HY, et al. CD8 + Foxp3+Regulatory T Cells Mediate Immunosuppression in Prostate Cancer. Clin. Cancer Res. 2007;13(23):6947–6958.
   PubMed Web of Science ®Google Scholar
• Getnet D, Maris CH, Hipkiss EL, et al. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J. Immunol. 2009;182(8):4675–4685.
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver KA, Anderson MJ, Stagliano K, et al. Cutting Edge: tumor-Specific CD8 + T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells. J. Immunol. 2009;183(8):4848–4852.
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2001;98(25):14565–14570.
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Musiani P, Pompa P, et al. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin. Cancer Res. 2011;17(6):1571–1581.
   PubMed Web of Science ®Google Scholar
• Tang S, Moore ML, Grayson JM, et al. Increased CD8 + T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells. Cancer Res. 2012;72(8):1975–1985.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–475.
   PubMed Web of Science ®Google Scholar
• Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516–531.
   PubMed Web of Science ®Google Scholar
• Reznik E, Luna A, Aksoy BA, et al. A landscape of metabolic variation across tumor types. Cell Syst. 2018;6(3):301–313.e3.
   PubMed Web of Science ®Google Scholar
• Massie CE, Lynch A, Ramos-Montoya A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719–2733.
   PubMed Web of Science ®Google Scholar
• Han W, Gao S, Barrett D, et al. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene. 2018;37(6):710–721.
   PubMed Web of Science ®Google Scholar
• Singh KB, Hahm E-R, Singh SV. Abstract 831: c-Myc is a novel target of prostate cancer cell growth inhibition by honokiol. Cancer Res. 2016;76(4):831.
   PubMedGoogle Scholar
• Sena LA, Denmeade SR. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Res. 2021;canres.1392.2021.
   Google Scholar
• Michalek RD, Gerriets VA, Jacobs SR, et al. Cutting Edge: distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4 +T Cell Subsets. J. Immunol. 2011;186(6):3299–3303 .
   PubMed Web of Science ®Google Scholar
• Gerriets VA, Kishton RJ, Nichols AG, et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J. Clin. Invest. 2015;125(1):194–207.
   PubMed Web of Science ®Google Scholar
• Hossain F, Al-Khami AA, Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 2015;3(11):1236–1247.
   PubMed Web of Science ®Google Scholar
• Wang H, Franco F, Tsui Y-C, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 2020;21(3):298–308.
   PubMed Web of Science ®Google Scholar
• Dunn SE, Ousman SS, Sobel RA, et al. Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity. J. Exp. Med. 2007;204(3):693.
   Web of Science ®Google Scholar
• Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46(5):681–686. discussion 686-7.
   PubMed Web of Science ®Google Scholar
• Bander NH, Yao D, Liu H, et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate. 1997;33(4):233–239.
   PubMed Web of Science ®Google Scholar
• Carretero FJ, Del Campo AB, Flores-Martín JF, et al. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunol. Immunother. 2016;65(1):47–59.
   PubMed Web of Science ®Google Scholar
• Younger AR, Amria S, Jeffrey WA, et al. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 2008;11(4):334–341.
   PubMed Web of Science ®Google Scholar
• Axelrod ML, Cook RS, Johnson DB, et al. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 2019;25(8):2392–2402.
   PubMed Web of Science ®Google Scholar
• Mao W, Ghasemzadeh A, Freeman ZT, et al. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J Immunother Cancer. 2019;7(1). https://doi.org/10.1186/s40425-019-0758-y.
   Google Scholar
• Kagoya Y, Nakatsugawa M, Yamashita Y, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 2016;126(9):3479–3494.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES. A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist. 2019;24(4):430–432.
   PubMed Web of Science ®Google Scholar